Personalized and Precision Medicine Journal

Abstract Chancroid is an STI characterized by the Gram-negative bacteria Haemophilus ducreyi. Controlling chancroid is challenging, and the primary treatment accessible is antimicrobial therapy. However, drug resistance has been seen in places where the disease is common. Due to recent global outbreaks of sexually transmitted infections (STIs), it is crucial to continue researchi ng innovative treatment options and prevention measures. We used reverse vaccinology and subtraction genomic methods to determine potential vaccination and therapeutic targets against H. ducreyi in silico. We found 56 Secreted proteins, with 159 membrane molecules and 515 cytoplasmic proteins. We assessed their need, operation, and ability to cause disease. We identified 6 potential vaccination targets and three pharmacological targets inside pathogenicity islands. The discovered targets may be utilized in future initiatives to manage chancroid globally.

Abstract Due to the increasing level of bacterial antibiotic resistance (AB), it is now required to modify the dosage for customized medication using therapeutic drug monitoring. The creation of a novel treatment for clinical use, such as situations of bacterial resistance, has been hailed as a feasible, affordable, and quick alternative by the pharmaceutical industry. Therefore, the current research sought to examine the myorelaxant Thiocolchicosidum's antibacterial activity against bacterial strains. Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Proteus mirabilis ATCC 25933, and Pseudomonas aeruginosa ATCC 27853 were used as the bacteria in an in vitro experimental study, along with the protocols for antibacterial activity screening, minimum inhibitory concentration (MIC), and characterization of antibacterial activity. Thiocolchicosidum, at levels varying from 0.48 to 1000 µg/mL, was the chemical. The only bacterial strains that showed any sensitivity to the myorelaxant were E. coli and P. aeruginosa, both of which had MICs of 500 µg/mL and 1000 µg/mL, respectively. Thiocolchicosidum demonstrated a bacteriostatic effect in the antimicrobial characterization test. Therefore, despite the fact that this medication is already considered safe for human use, no discernible antibacterial effects were shown in common bacterial strains. Therefore, research is required to determine how it differs from other microbes, such as various kinds of bacteria, fungus, and protozoa, in order to rule it out as a potential antibiotic material for use in industry.